← Back to Search

NEURESCUE device for Cardiac Arrest (ARISE Trial)

N/A
Recruiting
Led By David Shavelle, M.D.
Research Sponsored by neurescue
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up assessed up to 10 min
Awards & highlights

ARISE Trial Summary

This trial will show whether the NEURESCUE device, which is inserted through the femoral artery, can improve blood flow to the heart and brain in adults experiencing cardiac arrest.

Eligible Conditions
  • Cardiac Arrest
  • Cardiovascular Disease

ARISE Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~assessed up to 10 min
This trial's timeline: 3 weeks for screening, Varies for treatment, and assessed up to 10 min for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Successful balloon inflation within 10 minutes from first vessel puncture
Secondary outcome measures
Change in central blood pressure
Rate of occlusion success
Return of spontaneous circulation (ROSC)
+2 more

ARISE Trial Design

1Treatment groups
Experimental Treatment
Group I: TreatmentExperimental Treatment1 Intervention
The NEURESCUE device will be used as an adjunct to ACLS.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
NEURESCUE device
2022
N/A
~10

Find a Location

Who is running the clinical trial?

neurescueLead Sponsor
2 Previous Clinical Trials
10 Total Patients Enrolled
2 Trials studying Cardiac Arrest
10 Patients Enrolled for Cardiac Arrest
David Shavelle, M.D.Principal InvestigatorLong Beach Medical Center
~4 spots leftby Jun 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top